Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Modified Preloaded System for Renal Arteries in Fenestrated Endografting (MPSRA) (MPSRA)

4 febbraio 2022 aggiornato da: Enrico Gallitto, University of Bologna

Modified Preloaded System for Renal Arteries in Fenestrated Endografting

Advanced Endovascular repair of aneurysms and dissections involving thoraco-abdominal (type I-IV) and complex abdominal (juxta and para-renal) aorta is a ground-gaining procedure allowing favorable results in high surgical risk patients. The availability of iliac vessels navigation and the major role of lower leg perfusion in order to decrease the risk of spinal cord ischemia during these complex procedures, led to the development of devices with lower sheaths sizes and to the improvement of the technique with preloaded devices for visceral vessels in order to navigate in hostile anatomies or when an iliac access is not available. The aim of the study is to evaluate in a prospective single center observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries in fenestrated endografting in the routine treatment of paravisceral and thoraco-abdominal aortic pathologies.

Panoramica dello studio

Descrizione dettagliata

Thoracoabdominal aortic aneurysm (TAAA) and complex abdominal aortic aneurysms (AAA) represents an evolving pathology that involves to varying degrees both the descending thoracic aorta and the abdominal aorta. These aneurysms, according to their localization and involvement in the thoracic and abdominal aorta, have been classified according to Crawford into 4 groups (I-IV) for the TAAA and in pararenal/juxtarenal (p/j-AAA) for AAA when a standard endovascular repair is not possible.

The prevalence of these pathologies is currently not well known, but high mortality rates are reported in the population carrying TAAAs and j/p-AAAs that have not undergone surgical treatment, most of which are due to aortic rupture.

Among of the main complications related to TAAA endovascular repair and to complex AAA we can account spinal cord ischemia, lower leg ischemia and logo-operative times, that all can contribute to decrease overall technical and clinical success.

A particular subgroup of TAAAs is represented by post-dissection thoracoabdominal aneurysms (PDTAA), which represents an evolving pathology and one of the main chronic complications in outcomes of acute chronic dissection. In these particular subset of patients, as well as in patient with highly calcified and hostile accesses, the risk of post-operative spinal cord ischemia is higher and the availability of both iliac access navigability is not always possible, leading to technical failure, intraoperative complications and need for adjunctive invasive procedures in high surgical risk patients.

The fenestrated and branched endoprostheses (F/B-EVAR) represent a technology that is now firmly used for the treatment of thoraco-abdominal degenerative aneurysmal pathology in superspecialized centers. Recently, the technology with F/B-EVAR has also been used in the treatment of PDTAA, IMH and PAU, showing satisfactory results. This experience has been carried out in some centers, in the absence, however, of a wider and generalized experience. All these type of endografts are custom-made devices, requiring therefore a lading time for production and delivering before being implanted into the specific patient.

In order to overcome main drawbacks of these procedures, such us long operating time due to fenestrations and vessels cannulation, to avoid bilateral lower limbs ischemia due to large bore introducer sheaths and to accomplish successful delivery even in patient without navigability of both iliac accesses, a modified preloaded system for renal arteries has been developed by Cook (Cook Medical, Bloomington, IN, USA).

The aim of the study is to evaluate in a prospective single center study observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries developed by Cook Medical with bi-port handle system in the field of fenestrated endografting during the routine treatment of thoraco-abdominal and paravisceral abdominal aortic pathologies.

Tipo di studio

Osservativo

Iscrizione (Anticipato)

35

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Emilia Romagna
      • Bologna, Emilia Romagna, Italia, 40138
        • Reclutamento
        • University of Bologna
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

All elective patients treated in a single center institution, with the standard of care for thoraco-abdominal and para-juxta-renal abdominal aortic aneurysms using fenestrated/branched custom-made endograft developed by Cook Medical with modified preloaded system for renal arteries.

Descrizione

Inclusion Criteria:

  • Diagnosis of thoraco-abdominal or complex abdominal aortic aneurysm confirmed by a Computed tomography Angiography (CTA).
  • Etiologies will be degenerative aneurysms, inflammatory aneurysms, chronic post-dissectional aneurysms, penetrating aortic ulcers, failure of prior surgical or endovascular repair.
  • Elective aneurysmal repair of patient with maximum diameter greater than 55 mm, or fast growing, or symptomatic aneurysms.
  • Endovascular repair performed using custom-made fenestrated and/or branched endografting with presence of modified preloaded system with modified handle and preloaded catheters for visceral vessels cannulation.

Exclusion Criteria:

  • Patients submitted to advanced fenestrated and branched endovascular repair with other grafts besides the Cook Medical custom-made endograft or without modified handle preloaded delivery system.
  • Physician-modified devices
  • Patient treated with hybrid and/or open technique as well as parallel grafts (such as chimney/snorkel/periscope)
  • Patient treated as emergent/urgent patients or aneurysmal rupture
  • Patient who can not wait for the lead time required for endograft production and delivery.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Technical Success
Lasso di tempo: Intra-operative final completion angiography.
Successful deployment of custom-made modified endograft, target vessel patency and aneurysm exclusion, in absence of intra-operative mortality.
Intra-operative final completion angiography.
Mortality
Lasso di tempo: Within the first 30-days from the procedure.
Assessment of mortality related to procedure
Within the first 30-days from the procedure.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cardiovascular Adverse Events
Lasso di tempo: Within the first 30-days from the procedure.
Cardiopulmonary and renal events related to the procedure.
Within the first 30-days from the procedure.
Neurologic Adverse Events
Lasso di tempo: Within the first 30-days from the procedure.
Incidence of Spinal Cord Ischemia (transient/permanent) and Stroke
Within the first 30-days from the procedure.
Vessel Instability
Lasso di tempo: Within the first 30-days from the procedure.
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
Within the first 30-days from the procedure.
Rate of early reintervention
Lasso di tempo: Within the first 30-days from the procedure.
Any re-intervention needed after the type of procedure and the specific reason
Within the first 30-days from the procedure.
Overall Survival
Lasso di tempo: Through study completion, an average of 1 year.
Assessment of mortality in the post-operative period
Through study completion, an average of 1 year.
Aorta Related Survival
Lasso di tempo: Through study completion, an average of 1 year.
Assessment of mortality in the post-operative period related to aortic procedure or aortic related death.
Through study completion, an average of 1 year.
Freedom from reintervention
Lasso di tempo: Through study completion, an average of 1 year.
Time from procedure to the first aortic related/procedure related reintervention
Through study completion, an average of 1 year.
Freedom from Vessel Instability
Lasso di tempo: Through study completion, an average of 1 year.
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
Through study completion, an average of 1 year.
Freedom from Major Endoleaks
Lasso di tempo: Through study completion, an average of 1 year.
Time from procedure to the presence of high-flow endoleak (TypeI/III) and from endoleak that required reintervention
Through study completion, an average of 1 year.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2019

Completamento primario (Anticipato)

1 giugno 2022

Completamento dello studio (Anticipato)

1 dicembre 2022

Date di iscrizione allo studio

Primo inviato

4 gennaio 2022

Primo inviato che soddisfa i criteri di controllo qualità

24 gennaio 2022

Primo Inserito (Effettivo)

4 febbraio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 febbraio 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 febbraio 2022

Ultimo verificato

1 febbraio 2022

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi